Drug intelligence / Profile preview

varsetatug masetecan + bevacizumab

Development stage: Unknown
Lead developer: CytomX
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Varseta-M + bevacizumab is a combination therapy being developed by CytomX Therapeutics for the treatment of second-line (2L) and third-line (3L) metastatic colorectal cancer (mCRC). Varseta-M (varsetatug masetecan; CX-2051) is a conditionally activated Probody antibody-drug conjugate (ADC) targeting the epithelial cell adhesion molecule (EpCAM). It is armed with a topoisomerase-1 inhibitor payload (masetecan) and is designed to remain inactive in systemic circulation, becoming activated by proteases within the tumor microenvironment to minimize off-tumor toxicity. Bevacizumab is a recombinant humanized monoclonal antibody that binds to and neutralizes vascular endothelial growth factor (VEGF), inhibiting angiogenesis. The combination aims to leverage the targeted cytotoxic effects of the EpCAM-directed ADC alongside the anti-angiogenic properties of bevacizumab to improve outcomes in advanced colorectal cancer.

Brand names: Varseta-M + bevacizumab
Other names: varsetatug masetecan + bevacizumab

Targets

TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)EPCAM (Epithelial cell adhesion molecule)

Beyond the preview

Go deeper on varsetatug masetecan + bevacizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on varsetatug masetecan + bevacizumab.

Explore the full profile